Moderna Inc

MRNA

NASDAQ. Currency in USD

118.25 +0.18 ( +0.15% )

Real time prices: September 30

Market Cap.
46.26B
Beta (5Y monthly)
1.69
Price/Earnings
3.77
EPS (TTM)
32.81
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
3.86M
1y Target Est.
271.12
Day's Range
118.08
-
122.58
52 Week's Range
115.03
-
376.65

Historical Summary

Performance
EPS growth
Share Buybacks

About Moderna Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.modernatx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
405.45M
Employees
3400
Address
200 Technology Square, Cambridge, MA, United States, 02139
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Latest news

Here's Why the Post-Pandemic World May Be Even Better for This Vaccine Maker
Here's Why the Post-Pandemic World May Be Even Better for This Vaccine Maker

Moderna's billion-dollar revenue may be just getting started.
By The Motley Fool - 1 day ago

1 in 5 of Americans don't know about new omicron-targeting COVID boosters, survey finds
1 in 5 of Americans don't know about new omicron-targeting COVID boosters, survey finds

A Kaiser Family Foundation survey found that about half of Americans have heard little or...
By MarketWatch - 2 days ago

Why Moderna Was a Sickly Stock Today
Why Moderna Was a Sickly Stock Today

A shuffle at the top of the executive ranks, combined with the continued decline of...
By The Motley Fool - 3 days ago

EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster
EMA Accepts Moderna's (MRNA) Filing for Omicron BA.4, BA.5 Booster

The EMA accepts Moderna's (MRNA) regulatory filing seeking authorization for bivalent COVID-19 booster vaccine, mRNA-1273.222,...
By Zacks Investment Research - 3 days ago

Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids
Pfizer (PFE), BNTX Seek EU Nod for Omicron Booster in Kids

Pfizer (PFE) and BioNTech seek to expand the EU label of their Omicron BA.4/BA.5-adapting bivalent...
By Zacks Investment Research - 3 days ago

These 2 Growth Stocks Have Fallen Out of Grace. Are They Buys?
These 2 Growth Stocks Have Fallen Out of Grace. Are They Buys?

These vaccine makers have lost much of the momentum they built earlier in the pandemic.
By The Motley Fool - 3 days ago

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know
Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $122.15 in the latest trading session, marking a -0.07% move from...
By Zacks Investment Research - 4 days ago

Why Moderna Stock Lagged the Market Today
Why Moderna Stock Lagged the Market Today

The company's latest regulatory advance is overshadowed by developments with another biotech.
By The Motley Fool - 4 days ago